A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

• Status: Not yet recruiting
• Trial end date: 2036-08-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC

Criteria

Inclusion Criteria:

• Participants who have received at least one dose of cilta-cel in a Janssen-sponsored clinical study

• Participants who have provided informed consent for this study